Eli Lilly Q2 2026 Earnings
Adj EPS $8.38 VS. $6.31 Y/Y - Rev $22.97B (est $20.59B) - Zepbound Rev $4.93B (est $4.64B) - Mounjaro Rev $9.9B (est $8.83B) - Sees FY Adj EPS $35.50 To $36.50, Saw $35.50 To $37 - Sees FY Rev. $85.0B To $87.0B, Saw $82.0B To $85.0B - Committed Addl $4.5B To Expand Manufacturing Sites - Raises Year Guidance
Story updates
11:00:12 AM UTC
SquawkNews
Eli Lilly Q2 2026 Earnings
11:05:28 AM UTC
SquawkNews
Adj EPS 56C (est 53C) - Net Sales $6.3B (est $6.13B) - Organic Rev. -1.3% (est -3.5%) - Sees FY Adj EPS $2.03 To $2.09, Saw $1.98 To $2.10 - FY Adj. Oper Profit -16% To -18%, Saw -14% To -18% - Sees FY Organic Net Sales -0.5% To -2%, Saw -1.5% To -3.5%
Adj EPS $8.38 VS. $6.31 Y/Y - Rev $22.97B (est $20.59B) - Zepbound Rev $4.93B (est $4.64B) - Mounjaro Rev $9.9B (est $8.83B) - Sees FY Adj EPS $35.50 To $36.50, Saw $35.50 To $37 - Sees FY Rev. $85.0B To $87.0B, Saw $82.0B To $85.0B - Committed Addl $4.5B To Expand Manufacturing Sites - Raises Year Guidance